Tesamorelin for Statin-Associated Cognitive Effects: Human Trial Evidence on GH Axis and Cognition
What's breaking down if you have Statin-associated cognitive effects
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why Tesamorelin might help you
- You are reading about Statin-associated cognitive effects — what breaks down matters before any compound name.
- Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.
Why Statins matters for you
- Drug: Statins
- What it does: Lipid management; debated cognitive/muscle side effects in subset.
- Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.
How these fit together
Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- Tesamorelin → GH axis / visceral fat
What the evidence actually shows
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 4
- Claims tagged human evidence: 5
- Claims tagged preclinical (animal/lab): 0
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 4
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.7 / 1.00 — moderate — human claims present in ledger
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults (source s1)
Baker 2012 RCT details and results on cognition.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (source s2)
Ellis 2025 trial outcomes on WC and cognition.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Growth hormone-releasing hormone effects on brain γ-aminobutyric acid and N-acetylaspartylglutamate (source s3)
Friedman 2013 brain imaging substudy findings.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Statins and Brain Fog: Confusing for Patients, Prescribers, and Me (source s4)
Summary of statin cognitive evidence level.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Evidence ledger 5 · tier-ranked · API
Model review1 contributions · 1 modelExpand the recursive review layer
/api/articles/tesamorelin-brain-fog/contributionsAsk this article · 7 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.